All News

Sacituzumab govitecan and pembrolizumab were recommended as category 1 regimens for metastatic triple-negative breast cancers based on 2 phase 3 trials.

Benjamin Garmezy, MD discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.

Persistent training and workflow gaps were listed as potential barriers of AYA care among oncologists.

The irinotecan-based ChemoSeed delivery mechanism is currently under investigation for patients with malignant glioma in a registrational phase 2 trial.

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial.

In the non-HLA-A*02 arm of the FLAMINGO-1 trial, breast recurrence rates were less than 1% following treatment with GLSI-100.

The primary end point of PFS was met in the phase 3 FOURLIGHT-1 trial assessing atirmociclib plus fulvestrant in patients with HR+/HER2– breast cancer.

In each decade since the launch of the journal ONCOLOGY, cancer care has evolved, and with it the finances and costs associated with these improving treatments.

Julian Hong, MD, MS, stated that the demand for highly specialized teams trained to combat the onset of mental health disorders outpaces the supply.

FcRH5 is emerging as a potentially highly active target for cellular therapies in multiple myeloma care, said Natalia Neparidze, MD.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.

Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.

Results from a phase 1b trial for givastomig in front-line HER2-negative, PD-L1–positive gastroesophageal cancer support the FDA’s decision.

Emergent phase 1 LuPARP study data suggest that metastatic castration-resistant prostate cancer could be treated with PARP inhibition and radionuclides.

Over the past 40 years, oncology shifted to precision care, smarter toxicity management, AI-guided guidelines, and equity, according to Julie Gralow, MD.

Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.

The updated NDA to the FDA included additional data and statistical analyses from existing clinical trials for pediatric and adult patients with glioma.

Twenty patients with low-to-intermediate risk, localized prostate cancer underwent successful implantation with the anti-androgen eluting implants.

Based on an independent data monitoring committee’s feedback, enrollment for the phase 3 TACTI-004 trial will be halted.

Lynette Fernandez-Cuesta, PhD, discussed how the Petersen Accelerator Grant will drive the development of real-time clinical biomarkers for aggressive lung NETs.

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

The addition of SBRT to an immunotherapy doublet did not significantly affect safety outcomes among patients with de novo metastatic RCC.

Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.

Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.

Treatment with rusfertide appears to reliably control hematocrit among those with polycythemia vera, according to Andrew Kuykendall, MD.

The adoption of bispecific antibodies in the community setting remains a great unmet need in multiple myeloma, according to Rajshekhar Chakraborty, MD.

Oliver Sartor, MD highlighted SBRT, hormonal therapy, and the PSMA-DC regimen for patients with biochemical recurrence and PSMA-PET–positive disease.

Yan Leyfman, MD, discussed the factors that may ultimately define the next era of transplant medicine across hematologic malignancies.